Edgewise Therapeutics, Inc.
NASDAQ: EWTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kevin Koch
- Employees
- 117
- Headquarters
- Boulder, United States
- IPO year
- 2021
- Market cap
- $4.0B
- Website
- https://www.edgewisetx.com
Loading EWTX…
Loading profile data…Frequently asked questions about EWTX
What does Edgewise Therapeutics, Inc. (EWTX) do?
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker mu...
Where does EWTX trade?
Edgewise Therapeutics, Inc. (EWTX) trades on the NASDAQ Global Select.
What sector is EWTX in?
Edgewise Therapeutics, Inc. (EWTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Edgewise Therapeutics, Inc.?
Kevin Koch is the chief executive officer of Edgewise Therapeutics, Inc. (EWTX).
Where is Edgewise Therapeutics, Inc. headquartered?
Edgewise Therapeutics, Inc. is headquartered in United States.
Does EWTX pay a dividend?
Edgewise Therapeutics, Inc. (EWTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EWTX go public?
Edgewise Therapeutics, Inc. (EWTX) completed its initial public offering in 2021.